Jubilant Pharmo

how big is Jubilant Pharmo?

As of Jun 06, Jubilant Pharmova Ltd has a market capitalization of 18,271.94 Cr, with recent net sales of 7,234.50 Cr and a net profit of 839.40 Cr for the latest four quarters.

Market Cap: As of Jun 06, Jubilant Pharmova Ltd has a market capitalization of 18,271.94 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported a sum of Net Sales of 7,234.50 Cr and a sum of Net Profit of 839.40 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are valued at 5,433.90 Cr, and the Total Assets amount to 11,315.80 Cr.

Who are in the management team of Jubilant Pharmo?

As of March 2023, the management team of Jubilant Pharmo includes Shyam S Bhartia (Chairman), Hari S Bhartia (Co-Chairman), Priyavrat Bhartia (Managing Director), and Arjun Shanker Bhartia (Joint Managing Director), along with several non-executive and independent directors. This diverse team oversees the company's governance and strategic direction.

As of March 2023, the management team of Jubilant Pharmo includes the following individuals:<BR><BR>1. Shyam S Bhartia - Chairman (Non-Executive)<BR>2. Hari S Bhartia - Co-Chairman & Non-Executive Director<BR>3. S Sridhar - Non-Executive & Independent Director<BR>4. Sudha Pillai - Non-Executive & Independent Director<BR>5. Ashok Misra - Non-Executive & Independent Director<BR>6. Vivek Mehra - Non-Executive & Independent Director<BR>7. Sushil Kumar Roongta - Non-Executive & Independent Director<BR>8. Priyavrat Bhartia - Managing Director<BR>9. Arjun Shanker Bhartia - Joint Managing Director<BR>10. Arun Seth - Non-Executive & Independent Director<BR>11. Arvind Chokhany - Whole Time Director & CFO<BR>12. Naresh Kapoor - Company Secretary & Compliance Officer<BR>13. R Kumar - Whole Time Director<BR>14. Shirish Gundopant Belapure - Independent Director<BR><BR>This diverse team includes both executive and non-executive members, contributing to the governance and strategic direction of the company.

What does Jubilant Pharmo do?

Jubilant Pharmova Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of ₹1,929 Cr and a net profit of ₹154 Cr for March 2025. The company, formerly known as Jubilant Life Sciences, has a market cap of ₹18,236 Cr and key metrics including a P/E ratio of 38.00 and a dividend yield of 0.44%.

Overview:<BR>Jubilant Pharmova Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Vam Organic Chemicals Limited' in 1978. It underwent several name changes, becoming 'Jubilant Organosys Limited' in November 2001, 'Jubilant Life Sciences Limited' in October 2009, and finally 'Jubilant Pharmova Limited' in February 2021. The most recent quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,929 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 154 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 18,236 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 38.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.44%<BR>- Debt Equity: 0.26<BR>- Return on Equity: 7.75%<BR>- Price to Book: 2.92<BR><BR>Contact Details:<BR>- Address: Bhartiagram Gajraula, Amroha Uttar Pradesh: 244223<BR>- Phone: 91-5924-267200<BR>- Email: investors@jubl.com/support@jubl.com<BR>- Website: http://www.jubilantpharmova.com

Has Jubilant Pharmo declared dividend?

Yes, Jubilant Pharmova Ltd has declared a 500% dividend, amounting to ₹5 per share, with an ex-date of August 2, 2024. The company has shown strong total returns over longer periods, despite some short-term fluctuations.

Jubilant Pharmova Ltd has declared a 500% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 500%<BR>- Amount per share: 5 per share<BR>- Ex-date: 02 Aug 2024<BR><BR>Dividend Yield: 0.44%.<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -5.83%, the dividend return was 0%, resulting in a total return of -5.83%.<BR><BR>For the 1 year period, the price return was 58.16%, the dividend return was 0.68%, leading to a total return of 58.84%.<BR><BR>Over the 2 years period, the price return was 235.09%, the dividend return was 2.44%, culminating in a total return of 237.53%.<BR><BR>In the 3 years period, the price return was 185.02%, the dividend return was 4.65%, which resulted in a total return of 189.67%.<BR><BR>During the 4 years period, the price return was 36.31%, the dividend return was 2.71%, giving a total return of 39.02%.<BR><BR>For the 5 years period, the price return was 98.97%, the dividend return was 2.94%, resulting in a total return of 101.91%.<BR><BR>Overall, Jubilant Pharmova Ltd has declared a significant dividend, and the total returns over various periods show a positive trend, particularly in the longer terms, indicating strong performance despite some short-term fluctuations.

Who are the peers of the Jubilant Pharmo?

Jubilant Pharmo's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life. In terms of management risk, growth, and capital structure, Jubilant Pharmo is rated average, while its 1-year return of 68.61% is higher than Natco Pharma's but lower than Blue Jet Health's 139.69%.

Peers: The peers of Jubilant Pharmo are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Concord Biotech, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life.<BR><BR>Quality Snapshot: Excellent management risk is observed at Concord Biotech, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Caplin Point Lab, Blue Jet Health, Natco Pharma, and Sai Life, and Average management risk is noted for Jubilant Pharmo. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have Below Average or Good growth ratings, with Divi's Lab. showing Below Average growth, and Concord Biotech showing Good growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Concord Biotech, and Caplin Point Lab, while Good is noted for Torrent Pharma, and Average for Jubilant Pharmo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Blue Jet Health at 139.69%, while Natco Pharma has the lowest at -13.50%. Jubilant Pharmo's 1-year return of 68.61% is significantly higher than Natco Pharma's but lower than Blue Jet Health's. Additionally, Natco Pharma and Concord Biotech have negative six-month returns.

Who are the top shareholders of the Jubilant Pharmo?

The top shareholders of Jubilant Pharma include Spb Trustee Company Pvt Ltd with 20.52%, 18 mutual fund schemes holding 3.66%, 151 foreign institutional investors at 17.22%, and East Bridge Capital Master Fund I Ltd as the largest public shareholder with 4.3%. Individual investors collectively own 17.75% of the shares.

The top shareholders of Jubilant Pharma include a mix of promoters and institutional investors. The majority shareholders are the promoters, with Spb Trustee Company Pvt Ltd holding the largest stake at 20.52%. <BR><BR>In terms of institutional holdings, 18 mutual fund schemes collectively hold 3.66% of the company, while 151 foreign institutional investors (FIIs) account for 17.22%. The highest public shareholder is East Bridge Capital Master Fund I Ltd, which holds 4.3%. Additionally, individual investors collectively own 17.75% of the shares.

Is Jubilant Pharmo overvalued or undervalued?

As of November 3, 2025, Jubilant Pharma is fairly valued with a PE ratio of 37.37 and an EV to EBITDA of 14.49, positioned between peers like Sun Pharma and Cipla, despite facing challenges with an -8.16% return over the past year.

As of 3 November 2025, the valuation grade for Jubilant Pharmo has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 37.37, an EV to EBITDA of 14.49, and a PEG ratio of 1.35. In comparison to its peers, Sun Pharma has a PE ratio of 35.62 and an EV to EBITDA of 24.18, while Cipla shows a more attractive PE of 22.44 and an EV to EBITDA of 5.66, indicating that Jubilant Pharmo is positioned in the middle range of its industry.<BR><BR>Despite recent stock performance showing a 4.09% gain over the past week compared to a -0.94% decline in the Sensex, the company's longer-term returns, particularly a -8.16% return over the past year, suggest some challenges ahead. Overall, the current valuation reflects a balance between growth expectations and market realities, placing Jubilant Pharmo in a fair valuation category amidst its peers.

How has been the historical performance of Jubilant Pharmo?

Jubilant Pharmo's historical performance shows fluctuating financial metrics, with net sales increasing from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025, despite a peak of INR 9,110.82 crore in March 2019. The company has rebounded in profitability, with profit after tax rising to INR 836.80 crore in March 2025 from a loss of INR 77.13 crore in March 2023.

Answer:<BR>The historical performance of Jubilant Pharmo shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Pharmo's net sales have shown a steady increase from INR 6,130.16 crore in March 2022 to INR 7,234.50 crore in March 2025. However, this is a decline from the peak of INR 9,110.82 crore in March 2019. The total operating income followed a similar trend, reaching INR 7,234.50 crore in March 2025. The total expenditure, excluding depreciation, increased from INR 4,973.83 crore in March 2022 to INR 6,060.80 crore in March 2025. Operating profit (PBDIT) has fluctuated, peaking at INR 1,739.01 crore in March 2019 and dropping to INR 1,230.50 crore in March 2025. Profit before tax saw a significant recovery to INR 981.10 crore in March 2025, up from just INR 15.53 crore in March 2023. Profit after tax also rebounded to INR 836.80 crore in March 2025, compared to a loss of INR 77.13 crore in March 2023. The company's total assets increased from INR 9,829.60 crore in March 2022 to INR 12,499.00 crore in March 2025, while total liabilities rose from INR 9,829.60 crore to INR 12,499.00 crore in the same period. Cash flow from operating activities improved to INR 1,072.00 crore in March 2025, indicating a positive trend in cash generation. Overall, Jubilant Pharmo has demonstrated resilience with a recovery in profitability and growth in sales, despite facing challenges in previous years.

Is Jubilant Pharmo technically bullish or bearish?

As of December 3, 2025, Jubilant Pharma's technical trend has shifted to a bearish outlook, supported by mildly bearish MACD and KST indicators, alongside mixed signals from moving averages and Bollinger Bands.

As of 3 December 2025, the technical trend for Jubilant Pharmo has changed from mildly bullish to sideways. The current technical stance is bearish, with key indicators supporting this view. The MACD is mildly bearish on both the weekly and monthly time frames, and the KST also shows a mildly bearish trend. The Bollinger Bands indicate a bearish sentiment on the weekly chart, while the moving averages on the daily chart are mildly bullish, suggesting mixed signals. Overall, the weakness in the weekly indicators and the sideways trend suggest a bearish outlook with limited strength.

When is the next results date for Jubilant Pharmova Ltd?

The next results date for Jubilant Pharmova Ltd is February 6, 2026.

The next results date for Jubilant Pharmova Ltd is scheduled for February 6, 2026.

Are Jubilant Pharmova Ltd latest results good or bad?

Jubilant Pharmova Ltd's latest results show a 16.51% revenue growth to ₹2,122.50 crores, but a concerning 44.60% decline in net profit to ₹55.90 crores and a significant drop in operating margin indicate serious financial challenges, making the overall results unfavorable.

Jubilant Pharmova Ltd's latest results indicate a challenging quarter for the company. While it achieved a significant revenue growth of 16.51% year-on-year, reaching ₹2,122.50 crores, this positive top-line performance was overshadowed by a dramatic decline in net profit. The net profit fell by 44.60% year-on-year to ₹55.90 crores, which raises concerns about the company's profitability and operational efficiency.<BR><BR>The operating margin also contracted sharply, dropping to 13.68% from 17.44% in the previous quarter, indicating significant cost pressures. This margin compression, coupled with a high tax rate of 40.26%, has led to a profit after tax margin of only 2.64%, the lowest since Q4 FY24.<BR><BR>Overall, while the revenue growth is a positive sign, the substantial profit decline and operational challenges suggest that the company's financial health is under severe pressure. Therefore, the results can be characterized as bad, reflecting deeper issues that need to be addressed for sustainable growth.

Should I buy, sell or hold Jubilant Pharmova Ltd?

Why is Jubilant Pharmova Ltd falling/rising?

As of 17-Mar, Jubilant Pharmova Ltd's stock price is at 836.25, reflecting a decline of 0.48%. The stock has underperformed significantly, with a year-to-date decline of 22.19% compared to the Sensex's 10.74%, and shows reduced investor interest and declining financial performance.

As of 17-Mar, Jubilant Pharmova Ltd's stock price is falling, currently at 836.25, which reflects a decrease of 4.0 points or 0.48%. The stock has been underperforming, having lost 1.06% over the last two days and is currently trading below several key moving averages, specifically the 20-day, 50-day, 100-day, and 200-day averages, although it is higher than the 5-day moving average.<BR><BR>In terms of performance relative to the benchmark, the stock has shown a year-to-date decline of 22.19%, significantly worse than the Sensex's decline of 10.74%. Over the past month, it has decreased by 6.90%, while the Sensex has fallen by 8.84%. This trend indicates a consistent underperformance compared to the broader market.<BR><BR>Investor participation has also declined, with delivery volume dropping by 25.96% compared to the 5-day average, suggesting reduced interest from investors. Furthermore, the stock's performance today has underperformed its sector by 1.26%.<BR><BR>Despite having a relatively attractive valuation with a return on capital employed (ROCE) of 9.9 and high institutional holdings at 27.18%, the company faces challenges. Over the past five years, its operating profit has decreased at an annual rate of 8.16%, and recent financial results have shown significant declines, including a 31.1% drop in profit after tax for the most recent quarter.<BR><BR>These factors collectively contribute to the stock's current downward trajectory.

Why is Jubilant Pharmova Ltd falling/rising?

As of 18-Mar, Jubilant Pharmova Ltd's stock price is rising to 851.00, indicating a potential trend reversal after previous declines. Despite a challenging year-to-date performance, the stock's attractive valuation and high institutional holdings suggest short-term positive sentiment, though long-term growth prospects remain concerning.

As of 18-Mar, Jubilant Pharmova Ltd's stock price is rising, currently at 851.00, reflecting an increase of 14.75 (1.76%). This upward movement is notable as it comes after two consecutive days of decline, indicating a potential trend reversal. The stock has outperformed its sector by 1.49% today and reached an intraday high of Rs 861, which is a 2.96% increase.<BR><BR>Despite a challenging year-to-date performance, where the stock has declined by 20.82%, the recent rise can be attributed to several factors. The stock is currently trading at a discount compared to its peers' average historical valuations, suggesting an attractive valuation with a return on capital employed (ROCE) of 9.9. Additionally, high institutional holdings at 27.18% indicate confidence from larger investors who typically have better resources to analyze company fundamentals.<BR><BR>However, it is important to note that the stock's long-term growth prospects remain concerning, with an annual operating profit decline of 8.16% over the past five years. Furthermore, the recent quarterly results showed a significant drop in profit after tax (PAT) by 31.1%, which may temper enthusiasm among investors. Nonetheless, the current rise in stock price reflects a short-term positive sentiment, possibly driven by the stock's attractive valuation and recent performance relative to its sector.

Why is Jubilant Pharmova Ltd falling/rising?

As of 19-Mar, Jubilant Pharmova Ltd's stock price is Rs 842.00, down 1.72%, with a year-to-date decline of 21.66%. Despite high institutional holdings, the company's financial health is concerning due to declining profits and reduced investor interest.

As of 19-Mar, Jubilant Pharmova Ltd's stock price is falling, currently at Rs 842.00, which reflects a decrease of Rs 14.7 or 1.72%. The stock has underperformed compared to the broader market, with a year-to-date decline of 21.66%, significantly worse than the Sensex's drop of 12.92%. <BR><BR>Today's performance indicates a negative trend, as the stock touched an intraday low of Rs 836.75, marking a decline of 2.33%. Additionally, the Pharmaceuticals & Drugs sector has also seen a downturn, falling by 2.11%. The stock's liquidity appears to be decreasing, with delivery volume on March 18 dropping by 57.3% compared to the 5-day average, suggesting reduced investor interest.<BR><BR>While the company has high institutional holdings at 27.18%, indicating some level of confidence from larger investors, the overall financial health shows concerning signs. The operating profit has declined at an annual rate of 8.16% over the last five years, and recent quarterly results have been disappointing, with a 31.1% fall in profit after tax. These factors contribute to the stock's current decline, overshadowing its attractive valuation and the slight outperformance against its sector today.

Why is Jubilant Pharmova Ltd falling/rising?

As of 20-Mar, Jubilant Pharmova Ltd's stock is at Rs 827.80, down 2.66%, reflecting a broader negative trend with a year-to-date decline of 22.98%. Despite some positive factors, overall sentiment is negative due to poor performance and reduced investor interest.

As of 20-Mar, Jubilant Pharmova Ltd's stock price is falling, currently at Rs 827.80, reflecting a decrease of Rs 22.65 or 2.66%. This decline is part of a broader trend, as the stock has underperformed the sector by 4.36% today and has experienced consecutive losses over the past two days, totaling a drop of 3.37%. <BR><BR>The stock's performance over various periods also indicates a negative trajectory, with a year-to-date decline of 22.98% compared to a 12.54% drop in the benchmark Sensex. Additionally, the stock has been trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume falling by 32.53% against the 5-day average, indicating reduced interest in the stock. Furthermore, the company has reported poor long-term growth, with an operating profit decline of 8.16% annually over the last five years, and negative quarterly results, including a 31.1% fall in profit after tax.<BR><BR>While there are some positive factors, such as a relatively attractive valuation and high institutional holdings, the overall sentiment remains negative due to the stock's poor performance and declining investor confidence.

Which are the latest news on Jubilant Pharmo?